GenSight Biologics Announces Its 2024 Financial Calendar

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024

GenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital

GenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business Update

Laurence Rodriguez, appointed CEO of GenSight Biologics in December 2023, joins the Company’s Board of Directors

GenSight Biologics Provides Business and Financial Update